Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096950 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury
A Phase 1 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04096950: Completed Phase 1 study, sponsored by Tanabe Pharma America.
NCT04096950 is a Phase 1 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04096950, a Phase 1 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.
Interventions
- BIOLOGICAL MT-3921 Low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-04-19 |
| Est. Completion | 2021-01-06 |
| Phase | Phase 1 |
What the finished NCT04096950 record still lists
NCT04096950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which MT-3921 Low dose is the first listed.
NCT04096950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04096950 about?
NCT04096950 is a clinical study titled "Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.
What is the current status of trial NCT04096950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-04-19. Estimated completion is 2021-01-06.
What interventions are being tested in trial NCT04096950?
The interventions under investigation include: MT-3921 Low dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT04096950?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04096950's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI